Select a Region North America

Expertise

Sid Bhat

Manager, Commercial Strategy

Expertise:

Commercialization

Sid is a Business Strategy leader with 8+ years of experience in the life sciences and healthcare industry. He currently leads Large Pharma Commercial Strategy at EVERSANA, where he directs the identification and securing of revenue opportunities for EVERSANA within large pharma products. He has led the EVERSANA REIGNITE initiative, EVERSANA’s commercial solution for established brands in large pharma.

Prior to EVERSANA, Sid held business strategy and commercial roles at life sciences companies and management consulting firms in APAC, MENA, and North America. He has advised senior management on a range of topics including go-to-market and mature brand strategies.

Sid has an MBA from Case Western Reserve University and is a certified sports physical therapist in the UK and India. He is passionate about the life sciences industry and is committed to making a difference in the lives of patients.

Articles by Sid Bhat

Balancing the Portfolio: How Extending Mature Brands’ Success Can Replenish Costs Invested In Launching New Products

The traditional mindset toward established brands in the pharmaceutical industry has largely been to let focus fade from them and shift entirely to developing and launching new products. With emphasis placed almost exclusively on new product launches, mature brands are essentially starved of any resources to keep them healthy and vital, even if they are still generating hundreds of millions of dollars in revenue.  Declaring mature brands lifeless well before their time is one of the most common mistakes manufacturers make. While a decline in revenue is inevitable for established brands as loss of exclusivity (LOE) approaches, incremental investments can greatly decrease that decline and yield significant returns. Companies should […]

Asset Optimization: Breathe New Life Into Mature Brands with EVERSANA REIGNITE™

Maximizing revenue potential throughout products’ entire lifecycles before they reach loss of exclusivity (LOE) is the most impactful return on investment manufacturers can make for their established brands. While many companies figuratively put their mature brands out to pasture to invest more in new products, they ignore the significant revenue still to be gained from a loyal base of patients, physician advocates and overall brand awareness. These products tend to be highly promotionally responsive at this point in their lifecycle, and their revenue can be leveraged to replenish investments into new brands that often take years to see prosperity.  By looking at asset optimization across different confounding variables, achieving ample […]

Interested in scheduling a meeting or speaking event?

お問い合わせ